In December 2023, China’s National Healthcare Security Administration (NHSA) published the 2023 National Reimbursement Drug List (2023 NRDL), implementing a comparable level of pricing discounts to those seen in 2021.
ASPE - Changes in the List Prices of Prescription Drugs, 2017-2023 ZS - Exploring 2025 pharma industry trends, outlook and strategies FDA - National Drug Code Database Background Information ASPE - Medicare Drug Price Negotiation Program More… ↓ ⤷ SubscribeMake...
[1] Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026. (n.d.). Centers for Medicare & Medicaid Services. https://www.cms.gov/files/document/fact-sheet-medicare-selected-drug-negotiation-list-ipay-2026.pdf [2] Rapfogel, N. (2023, August 30). ...
Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products. U.S. FDA Approves Expanded Label for Astellas' Izer...
The average price of newly admitted drugs through negotiation and bidding dropped by 60.1 percent, basically the same as 2021.
1.Delayed Effective Date and Consistent Price Cut Practice Unlike the 2021 price negotiation and the 2021 version of the National Reimbursement Drug List (NRDL) completed at the end of 2021, the negotiation for the 2022 version of the NRDL was delayed until early January 2023 and...
Written byGabriel Levitt, MA| Posted February 05, 2021 |Updated February 16, 2023 The Rand Corporation has released animpressive studyshowing that brand name drugs cost far more in the United States than in other countries – on average 344% more. For those of you looking for a methodological...
A rival from Bristol Myers Squibb called Opdivo had $9 billion in 2023 sales. Analysts project its peak at north of $11 billion in 2027. “It’s easy to look at the Humiras of the world, the Keytrudas, the Opdivos and say, ‘Yes, they returned an amazing (return on investment),...
Farxiga, Xarelto, Entresto, and Eliquis are shown at the New City Halsted Pharmacy, Aug. 29, 2023, in Chicago.Scott Olson/Getty Images "The Inflation Reduction Act's price-setting provisions are bad policy that will stifle the U.S. biopharmaceutical sector's research and development...
(IRA), and novel formulary access strategies have led multiple manufacturers to pop the gross-to-net bubble for high-list/high-rebate products. Consider the 18 products with list-price cuts shown below. Other drugmakers have reduced the rate of price increases, thereby inflating the bubble more...